NCT02404805View on ClinicalTrials.gov

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
HIVHepatitis C
Interventions
DRUG

dolutegravir

dolutegravir tablets 50mg, once daily x 7 days.

DRUG

simeprevir

simeprevir tablets 150mg, once daily x 7 days.

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02404805 - Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers | Biotech Hunter | Biotech Hunter